For example, the carriers of the PTPN22(C1858T) variant have a lower risk of non-melanoma skin cancer, while the homozygotes for the PTPN22(C1858T) have improved survival when treated with atezolizumab (anti-PDL1 antibody). The gene discussed is PTPN22; the disease is non-melanoma skin carcinoma.